Do you have patients referred to you suffering from NAFLD?Are you looking for an expert guide to the latest in clinical management?If so, this is the book for you, providing an expert and comprehensive analysis of NAFLD: what it is, why it happens, who is likely to suffer from it, and how to decide on the best management options for your patients.This book focuses clearly on providing first-rate clinical guidance as to the assessment, diagnosis and treatment of patients in the clinical setting, based wherever possible on the latest evidence and scientific understanding of disease mechanisms. With each chapter fully revised and updated with the very latest in AASLD, EASL and Asia-Pacific guidelines, this second edition provides:* Four brand new chapters, including "NAFLD and cardiovascular risk factors" and "Non-invasive methods to determine severity of NAFLD/ NASH"* A clear overview on the causative mechanisms of NAFLD* Self-assessment via key points and multiple-choice questions throughout* The very latest in clinical drug trials* Analysis of NAFLD in relation to obesity, diabetes, high cholesterol and liver cancer* A consideration of NAFLD importance in Asia (particularly including Japan and China) and South America, as well as Europe and North AmericaNAFLD is a serious condition that is increasing in prevalence globally from year to year. Non-Alcoholic Fatty Liver Disease: A Practical Guide, is essential reading for all hepatologists and health professionals managing patients who have this condition.

List of Contributors, vii1 What is non-alcoholic fatty liver disease (NAFLD), and why is it important? 1Geoffrey C. Farrell, Arthur J. McCullough, and Christopher P. Day2 NAFLD in the community, 17Leon A. Adams3 Pathology of NAFLD, 27Elizabeth M. Brunt and David E. Kleiner4 The natural history of NAFLD, 37Paul Angulo5 Emerging concepts on the pathogenesis of non-alcoholic steatohepatitis (NASH), 46Isabelle A. Leclercq6 Diabetes and NAFLD: why is the connection important? 62Elisabetta Bugianesi7 NAFLD and cardiovascular risk factors: implications for vascular disease, 71Giovanni Targher8 A primary care perspective of fatty liver: diagnosis, management, prescribing, and when to refer, 84Shivakumar Chitturi and Geoffrey C. Farrell9 Imaging of NAFLD, 93Takeshi Yokoo, An Tang, and Claude B. Sirlin10 Non-invasive methods to determine the severity of NAFLD and NASH, 112Vincent Wai-Sun Wong and Henry Lik-Yuen Chan11 Fatigue, quality of life, and psychosocial issues for people with NAFLD, 122Julia L. Newton and James Frith12 Physical activity and cardiovascular fi tness in patients with NAFLD: clinical importance and therapeutic implications, 132Ingrid J. Hickman, Graeme A. Macdonald, and Nuala M. Byrne13 NAFLD, obesity, and bariatric surgery, 149Philippe Mathurin14 Genetic predisposition to NAFLD and NASH: implications for pathogenesis, diagnosis, prevention, and management, 157Quentin M. Anstee, Ann K. Daly, and Christopher P. Day15 NAFLD in children, 171Ariel E. Feldstein16 The pointy end of the NAFLD iceberg: cirrhosis, portal hypertension, and liver failure, 182Jonathon W. Schwake, Dawn M. Torres, and Stephen A. Harrison17 Non-alcoholic fatty liver disease, hepatocellular cancer, and other cancers, 192Janine Graham and Helen L. Reeves18 NAFLD in Chinese and South Asian people, 206Jia-Horng Kao, Deepak Amarapurkar, and Jian-Gao Fan19 Non-alcoholic fatty liver disease in Japan, 217Takeshi Okanoue, Kohichiroh Yasui, and Yoshito Itoh20 Non-alcoholic fatty liver disease in South America and Hispanic people, 228Helma Pinchemel Cotrim and Carla Daltro21 Alcohol in non-alcoholic fatty liver disease: an oxymoron or a new standard of care?, 234Achuthan Sourianarayanane, Srinivasan Dasarathy, and Arthur J. McCullough22 Dietary factors in the pathogenesis and care of patients with fatty liver disease, 248Giulio Marchesini, Rebecca Marzocchi, Anna S. Sasdelli, Cristiana Andruccioli, and Silvia Di Domizio23 Metabolic factors and steatosis in patients with hepatitis B and C, 260Francesco Negro24 Drug therapy for NASH: insulin-sensitizing agents (metformin and thiazolidinediones), 271Mohammad S. Siddiqui and Arun J. Sanyal25 Hepatoprotectants against fatty liver disease: antioxidants, ursodeoxycholic acid, and herbal medicines, 284Anne Catherine Bürgi and Jean-François Dufour26 Lipid modifiers and NASH: statins, ezetimibe, fibrates, and other agents, 293Giovanni Musso, Federica Molinaro, Elena Paschetta, Roberto Gambino, and Maurizio CassaderIndex, 308Color plate section facing p86